Trazodone generates m-CPP: In 2008 risks from m-CPP might outweigh benefits of trazodone

References

• Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001; 4: 399–408
   PubMed Web of Science ®Google Scholar
• Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996; 42(5)573–581
   PubMed Web of Science ®Google Scholar
• Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008; 103(2)335–45
   PubMed Web of Science ®Google Scholar
• Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, et al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oraladministration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004; 37: 180–188
   PubMed Web of Science ®Google Scholar
• Flanagan SR, Greenwald B, Wieber S. Pharmacological treatment of insomnia for individuals with brain injury. J Head Trauma Rehabil 2007; 22(1)67–70
   PubMed Web of Science ®Google Scholar
• Gijsman HJ, Van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 1998; 18: 289–295
   PubMed Web of Science ®Google Scholar
• Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, et al. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine 2B and 5-hydroxytryptamine 2A receptors. J Pharmacol Exp Ther 2008; 324: 1136–1145
   PubMed Web of Science ®Google Scholar
• Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, et al. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 2006; 553: 171–184
   PubMed Web of Science ®Google Scholar
• Johanson CE, Kilbey M, Gatchalian K, Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, m-chlorophenylpiperazine and placebo. Drug Alcohol Depend 2006; 81: 27–36
   PubMed Web of Science ®Google Scholar
• Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 2007; 22: 234–8
   PubMed Web of Science ®Google Scholar
• Kast RE. Are we done with trazodone? The potential for damage by mCPP – a metabolite of trazodone. Acta Neuropsychiatr 2007; 19: 220–221
   Web of Science ®Google Scholar
• Kast RE, Altschuler EL. Dopamine agonists and valvular heart disease. New Engl J Med 2007; 356: 1677
   PubMed Web of Science ®Google Scholar
• Khaliq S, Irfan B, Haider S, Haleem DJ. m-CPP induced hypolocomotion does not interfere in the assessment of memory functions in rats. Pak J Pharm Sci 2008; 21: 139–143
   PubMed Web of Science ®Google Scholar
• Kovaleva J, Devuyst E, De Paepe P, Verstraete A. Acutechlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 2008; 30: 394–398
   PubMed Web of Science ®Google Scholar
• Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002; 8(10)1129–1135
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yobimoto K, Huong NT, Abdel-Fattah M, Van Hien T, Watanabe H. Psychological stress-induced enhancement of brain lipid peroxidation via nitric oxide systems and its modulation by anxiolytic and anxiogenic drugs in mice. Brain Res 1999; 839(1)74–84
   PubMed Web of Science ®Google Scholar
• Mercolini L, Colliva C, Amore M, Fanali S, Raggi MA. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma. J Pharm Biomed Anal 2008; 47: 882–887
   PubMed Web of Science ®Google Scholar
• Michel TM, Camara S, Tatschner T, Frangou S, Sheldrick AJ, Riederer P, et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 2008; 12: 1–7
   Google Scholar
• Mizoguchi Y, Monji A. Low-dose-trazodone-induced disorganized type psychosis. J Neuropsychiatry Clin Neurosci 2005; 17: 253–254
   PubMed Web of Science ®Google Scholar
• Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006; 22: 1703–1713
   PubMed Web of Science ®Google Scholar
• Nunes-de-Souza V, Nunes-de-Souza RL, Rodgers RJ, Canto-de-Souza A. 5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice. Behav Brain Res 2008; 187: 72–79
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal, SR, Trakht, I, Srinivasan, V, Spence, DW, Poeggeler, B, Hardeland, R, , et al. 2008. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry, 4: 1–13, [Epub ahead of print].
   Google Scholar
• Patel BN, Sharma N, Sanyal M, Shrivastav PS. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2008; 871(1)44–54
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149(10)725–733
   PubMed Web of Science ®Google Scholar
• Roth, T. 2009. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med, 10(1)19–25.
   PubMed Web of Science ®Google Scholar
• Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006; 169: 861–876
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New Engl J Med 2007; 356: 29–38
   PubMed Web of Science ®Google Scholar
• Schneider B, Pietri M, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, et al. Control of bioamine metabolism by 5-HT2B and alpha 1D autoreceptors through reactive oxygen species and tumor necrosis factor-alpha signaling in neuronal cells. Ann NY Acad Sci 2006; 1091: 123–141
   PubMed Web of Science ®Google Scholar
• Staack RF, Paul LD, Schmid D, Roider G, Rolf B. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?. J Chromatogr B Anal Technol Biomed Life Sci 2007; 855: 127–133
   PubMed Web of Science ®Google Scholar
• Varcoe TJ, Kennaway DJ. Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro. Brain Res 2008; 1209: 19–28
   PubMed Web of Science ®Google Scholar
• Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG. Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur Neuropsychopharmacol 2007; 17(10)637–642
   PubMed Web of Science ®Google Scholar